Atreca (USA: $BCEL) Ready For Biotech Boom 2022! 🧬

NASDAQ:BCEL   Atreca, Inc
Atreca , Inc. , a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a collaboration and license agreement with Xencor , Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology. Atreca , Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Your Intro To Penny Stock Trading Success...

1) Sign Up for our 100% Free Email Newsletter:

2) Follow our Telegram Channel @

3) Join our LIVE CHAT on Discord @

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.